Cannabis Market Size, Share & Trends Analysis Report By Product Type (Capsules, Concentrates, Edibles, Other Product Types), By Application (Medical, Recreational), By Compound Type (Tetrahydrocannabinol (THC), Cannabidiol (CBD), Balanced THC and CBD) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Cannabis Market Size

The global cannabis market size was valued at USD 41.03 billion in 2025 and is projected to grow from USD 47.04 billion in 2026 to USD 140.54 billion by 2034, registering a CAGR of 14.66% during the forecast period from 2026 to 2034. North America dominated the cannabis market with a market share of 48.2% in 2025.

The global legalization of it is propelled by its growing medical benefits, particularly in chronic pain relief. Simultaneously, the rising popularity of Cannabidiol (CBD) in skincare products, such as CBD Body Oil and CBD Face Cream, addresses skin hydration, reducing dryness, itching, and pain.

Cannabis is a genus of flowering plants used for thousands of years due to its widely acknowledged therapeutic and medical properties. Its use in social and spiritual contexts is likewise well documented. Three species predominate: C. Sativa, C. indica, and C. ruderalis. Most cultivars developed now are hybrids combining traits from two or more critical species. It is anticipated that the global market will rise during the projected period due to the increasing legalization of it, particularly for medicinal uses.

Cannabis Market Segmentation Analysis

By Product Type

The concentrates segment dominated the market and is estimated to register a CAGR of 15% during the forecast period. Marijuana concentrate is a concentrated mass containing tetrahydrocannabinol or THC as the main component. Marijuana concentrates are obtained via extraction. Solvents like carbon dioxide, butane, or ethanol extract cannabis concentrate from the marijuana plant. Marijuana concentrates, commonly called dabs, are available in various forms and are referred to by different names like shatter, budder, hash, live resin, and butane hash oil. They are consumed in several ways, such as via a water pipe or vaporizer, cooked in edibles, and rolled in joints. The increasing legalization of marijuana usage mainly drives segment growth over the forecast period.

The edible segment is the second largest. Edible marijuana is available in various forms in the global market. Brands like Diamond CBD Company, Everest, Bearly Legal, Kiva, Coda Signature, and others have introduced edible marijuana in the form of gummies, chocolates, candies, etc. Most marijuana edibles or cannabis-infused food products contain a significant amount of THC. THC-dominant edible marijuana products are mainly consumed for recreational and medical purposes. All such applications drive segment growth.

Request Customizationto receive a tailored report.

By Application

The recreational segment dominated the market and is estimated to register a CAGR of 14.7% during the forecast period. The growing global demand for it has propelled the need to develop better product delivery systems and sustainable product strains. This need has, in turn, led to many companies coming up with R&D, which extensively investigates several genetic improvement strategies for marijuana.

• For instance, Hydropothecary partnered with Segra in March 2018 to incorporate plant tissue propagation into marijuana production. This was done to help increase the yield of healthy plants and improve plant variants to serve the growing market for recreational marijuana.

The medical segment is the second largest. Cannabis and cannabinoid drugs are broadly utilized to treat diseases or alleviate symptoms in Australia, Canada, Germany, Israel, Peru, and Poland. In recent years, the involvement of marijuana in several physiological processes, such as blood pressure, appetite stimulation, and nausea and vomiting control, has led to the cultivation of medicinal marijuana across the world. In 2018, 29 nations, including the United Kingdom, Israel, Canada, Brazil, and Australia, approved Sativex, an oral spray made from the marijuana plant containing THC and CBD in a 1:1 ratio to treat spasticity in multiple ways of sclerosis. The synthetic cannabinoids dronabinol and nabilone are authorized for treating nausea and vomiting in AIDS patients and for weight loss in the U.S., the Netherlands, Germany, and Austria. Based on clinical trials, the suggested usage of CBD in medicinal products is 150-1500 mg/day. The medicinal properties of marijuana, increasing advances in genetic development, and intellectual property on it may expand the global market over the coming years.

By Compound Type

The Tetrahydrocannabinol (THC) segment dominates the market and is estimated to register a CAGR of 15.1% during the forecast period. Though it is better known for its mind-altering euphoria, THC has significant medical benefits. In December 2018, the United States removed marijuana with less than 0.3% THC on a dry weight basis under the Controlled Substance Act. Therefore, the usage of THC is anticipated to increase in North America. Companies have been extensively venturing into developing genetically improved high-yielding varieties with better harvestability and market quality, reliably low THC content, and improved herbicide tolerance of the marijuana crop. In the European Union, marijuana with less than 0.3 THC is considered an agricultural commodity or agricultural material. This has led to higher cultivation of marijuana in Europe in recent years. Therefore, the cultivation of marijuana for industrial applications, such as animal feed, woven textile fibers, and building materials, is likely to enhance the market during the forecast period.

Speak to an Analystto discuss market opportunities.

Regional Insights

North America: Dominant Region with A Cagr of 14.5%

North America's cannabis market is estimated to register a CAGR of 14.5% during the forecast period. It continues to enjoy widespread acceptance in the United States for recreational and therapeutic uses despite being a psychoactive drug. Till 2020, 15 states and two U.S. territories had legalized the recreational use of marijuana. Thirty-five states and four U.S. territories legalized cannabis for medicinal use. CV Sciences is among the major players in the United States, offering hemp-based phytocannabinoids, such as CBD oil, to the beauty care, pet care, nutraceuticals, specialty beverage, and functional food sectors. Therefore, the increasing instances of legalization of marijuana for medicinal and recreational use by adults are expected to drive the U.S. cannabis industry during the forecast period.

Unlock Regional Insightsto access country-level data, & regional trends.

South America: Fastest Growing Region

South America is the second largest region. It is estimated to reach an expected value of USD 18 billion by 2030 at a CAGR of 13.9% during the forecast period. The leading regulatory authorities with jurisdiction over cannabinoid drugs in Argentina are the Ministry of Health (MoH), the National Comprehensive Drug Policy Department (SEDRONAR), and the National Agency of Medicines, Foods, and Medical Technology (ANMAT). In March 2017, the country legalized the medicinal use of marijuana oils. Still, it maintained an existing prohibition on cultivating plants and possessing seeds by individuals or groups. With 2017 legislation, Argentina joined many South American countries to relax cannabis laws. Therefore, it is anticipated that the market in Argentina will expand significantly over the coming years because of the legalization of marijuana grown for medicinal purposes and new corporate alliances and expansions.

The third-largest region is Europe. Germany authorized medical marijuana in March 2017 to meet the rising demand from patients. Medical products of it are only available at pharmacies in Germany, where they are only given as a last resort after the patient has tried all other therapeutic options. The International Narcotics Control Board (INCB) reports that Germany imported around 7.6 metric tons of marijuana flowers, extracts, preparations, and finished therapeutic products in 2018, up from approximately 4.5 metric tons in 2017. Moreover, Germany's demand for medicinal products is expected to be around 16 metric tons in 2020. The cultivation of medical products in the country is approved based on the tender.

• For instance, in 2019, Germany's health regulator, the Federal Institute of Drugs and Medical Products (BfARM), allowed companies, Aurora, Aphria, and Nuuvera, to grow a total of 10,400 kilograms of medicinal marijuana over the next four years. This may support the market growth.

List of Key and Emerging Players in Cannabis Market